New Delhi, May 13 -- US President Donald Trump's proposal to reduce prescription drug prices in the US by 30 per cent to 80 per cent may have unintended global consequences, particularly for countries like India that currently enjoy lower pharmaceutical costs, according to the Global Trade Research Initiative (GTRI).

The plan centres on an executive order implementing a 'Most-Favoured Nation' (MFN) pricing policy, which GTRI Founder Ajay Srivastava believes will trigger a worldwide pharmaceutical price recalibration.

"It is likely to trigger a global price recalibration, with pharmaceutical giants intensifying pressure on lower-cost markets like India to raise their prices by tightening patent laws through trade negotiations," Srivastav...